Zhu Gang, Yang Shirong, Wang Ronglin, Lei Jie, Ji Peigang, Wang Jiancai, Tao Kai, Yang Chen, Ge Shunnan, Wang Liang
Department of Neurosurgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China.
Department of General Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China.
Neuropsychiatr Dis Treat. 2021 Feb 26;17:681-693. doi: 10.2147/NDT.S273578. eCollection 2021.
Glioblastoma multiforme (GBM) is an aggressive brain tumor with a rather short survival time. Mutation of p53 has been observed and reported to play critical roles in the progression of GBM. However, the pathological mechanisms are still unclear. This study was designed to identify the role of miR-154 in mediating the biological functions of p53 in glioblastoma multiforme.
In the current study, the expression of miR-154 in GBM tissue samples and cell lines with wt-p53 or mutant p53 was evaluated. The functions of miR-154 in tumor migration, invasion and epithelial-mesenchymal transition were analyzed in vitro. A luciferase reporter assay was used to identify the target of miR-154.
We found that expression of miR-154 was much lower in patient tissues with mutant p53. Further study revealed that p53 was a transcription factor of miR-154 and that the R273H mutation led to its inactivation. In addition, overexpression of miR-154 remarkably suppressed cell migration, invasion and EMT in vitro and tumor growth in vivo. Moreover, TCF12 was proven to be a direct target of miR-154, and the tumor suppressive effect of miR-154 was reversed by TCF12.
Overall, miR-154, which was regulated by wt-p53, inhibited migration, invasion and EMT of GBM cells by targeting TCF12, indicating that miR-154 may act as a biomarker and that the p53/miR-154/TCF12 pathway could be a potential therapeutic target for GBM.
多形性胶质母细胞瘤(GBM)是一种侵袭性脑肿瘤,生存时间较短。已观察到p53突变,并报道其在GBM进展中起关键作用。然而,其病理机制仍不清楚。本研究旨在确定miR-154在介导p53在多形性胶质母细胞瘤中的生物学功能中的作用。
在本研究中,评估了miR-154在具有野生型p53或突变型p53的GBM组织样本和细胞系中的表达。在体外分析了miR-154在肿瘤迁移、侵袭和上皮-间质转化中的功能。使用荧光素酶报告基因测定法鉴定miR-154的靶标。
我们发现,在具有突变型p53的患者组织中,miR-154的表达要低得多。进一步研究表明,p53是miR-154的转录因子,R273H突变导致其失活。此外,miR-154的过表达在体外显著抑制细胞迁移、侵袭和EMT,在体内抑制肿瘤生长。此外,TCF12被证明是miR-154的直接靶标,并且TCF12逆转了miR-154的肿瘤抑制作用。
总体而言,由野生型p53调控的miR-154通过靶向TCF12抑制GBM细胞的迁移、侵袭和EMT,表明miR-154可能作为一种生物标志物,并且p53/miR-154/TCF12途径可能是GBM的潜在治疗靶点。